Epilepsy: EEG Work-Up Timing, Antiseizure Titration & Convulsive Status Pathway

Epilepsy is a chronic neurological disorder characterised by an enduring predisposition to generate epileptic seizures—paroxysmal, transient signs or symptoms produced by abnormally synchronous or excessive neuronal activity in the brain. The 2014 International League Against Epilepsy (ILAE) practical clinical definition operationalises the diagnosis as at least two unprovoked seizures occurring more than 24 hours apart, one unprovoked or reflex seizure with a 10-year recurrence risk approximating that after two unprovoked events (commonly cited as ≥60%), or the diagnosis of a recognised epilepsy syndrome. Epilepsy may also be considered resolved when an age-dependent syndrome has been outgrown or when the patient has been seizure-free for at least 10 years with the last 5 years off antiseizure medications.

The pathophysiology is heterogeneous: cortical or subcortical networks become hyperexcitable through ion-channel dysfunction, altered neurotransmitter balance (most commonly excessive glutamatergic drive or reduced GABAergic inhibition), structural lesions such as mesial temporal sclerosis or cortical dysplasia, immune-mediated injury, or genetically programmed network instability. Seizures emerge when these networks recruit enough cortex synchronously to produce the clinical event, and the resulting semiology depends on which cortical regions are involved and how the discharge spreads.

Epilepsy is not a single disease. It is a spectrum that ranges from self-limited childhood syndromes with excellent outcomes—such as childhood absence epilepsy or self-limited epilepsy with centrotemporal spikes—to drug-resistant focal epilepsies after stroke or traumatic brain injury, and severe developmental and epileptic encephalopathies. Practical management therefore depends as much on identifying the seizure type and syndrome as on suppressing the seizures themselves.

The ILAE 2017 framework asks three questions in order: What is the seizure type? (focal, generalised, unknown onset), What is the epilepsy type? (focal, generalised, combined generalised and focal, unknown), and Is there an epilepsy syndrome? Aetiology (structural, genetic, infectious, metabolic, immune, unknown) and comorbidities are layered on top. This three-tier approach drives both prognosis counselling and rational drug selection.

↔On a small screen, swipe or scroll sideways to see the full table.

High-yield syndrome anchors

• Childhood absence epilepsy and juvenile absence epilepsy: generalised genetic epilepsies with brief staring spells, sometimes with later tonic-clonic seizures.
• Juvenile myoclonic epilepsy: early-morning myoclonus, photosensitivity, generalised tonic-clonic seizures—usually responds well to broad-spectrum therapy but typically requires long-term treatment.
• Temporal lobe epilepsy with hippocampal sclerosis: the archetypal drug-resistant focal epilepsy and the most surgically remediable form.
• Frontal lobe epilepsy: brief, often nocturnal, hyperkinetic events that can mimic parasomnia or psychogenic events.
• Lennox–Gastaut and Dravet syndromes: developmental and epileptic encephalopathies that need specialist multimodal care.

Syndrome labels evolve as the ILAE updates nosology; always align documentation with the working diagnosis from the epilepsy specialist rather than retrospective relabelling on the ward.

Seizure semiology depends on the cortical network involved and how the discharge propagates. Documenting what happened, in what order—not just the label “seizure”—drives classification, drug choice, and prognosis discussions.

Common presenting features

• Loss of consciousness with or without warning aura.
• Tonic stiffening followed by clonic jerking, often with cyanosis and stertorous breathing.
• Lateral tongue biting, urinary or faecal incontinence (specific but not sensitive for generalised tonic-clonic events).
• Postictal confusion, headache, muscle aches, or transient focal neurological deficit (Todd’s paresis).
• Behavioural arrest with automatisms (lip-smacking, fumbling) suggesting temporal lobe origin.

Auras & focal warnings

• Epigastric rising sensation—classic for mesial temporal seizures.
• Olfactory or gustatory hallucinations, déjà vu, or jamais vu.
• Unilateral paraesthesia, visual phenomena, or speech arrest pointing to the originating cortex.

Atypical & easily missed presentations

• Older adults with brief episodes of altered mental status or memory problems mistakenly attributed to dementia.
• Nocturnal hyperkinetic events misread as parasomnia, particularly in frontal lobe epilepsy.
• Patients with intellectual disability presenting with new behavioural change, which may be subtle non-convulsive seizures.
• Postictal psychosis or prolonged disorientation following clusters of focal impaired awareness seizures.

Why does epilepsy develop?

ILAE aetiological categories with practical cues

• Structural: previous stroke, traumatic brain injury, hypoxic-ischaemic injury, mesial temporal sclerosis, cortical dysplasia, brain tumour, cavernoma, or perinatal injury.
• Genetic: idiopathic generalised epilepsies and many developmental and epileptic encephalopathies (e.g. SCN1A in Dravet syndrome). Family history of epilepsy or febrile seizures raises suspicion but is neither sensitive nor specific.
• Infectious: bacterial meningitis, viral encephalitis, neurocysticercosis (a leading global cause), HIV-related CNS disease, tuberculoma.
• Metabolic: mitochondrial disease, pyridoxine-dependent epilepsy, urea cycle disorders, cerebral folate deficiency—rarer but actionable.
• Immune-mediated: antibody-mediated autoimmune encephalitis and the broader spectrum of autoimmune epilepsy—suspect with rapid progression, MRI mesial temporal change, or psychiatric prodrome.
• Unknown: still common despite optimal investigation; does not preclude effective treatment.

Common precipitants in established epilepsy

• Missed antiseizure medication doses or abrupt switches between brands without prescriber input.
• Sleep deprivation, alcohol binges, or alcohol withdrawal.
• Acute illness with fever, dehydration, or electrolyte derangement.
• Drug interactions—particularly enzyme inducers/inhibitors, hormonal contraception, antibiotics, and psychotropics.
• Photic stimulation in photosensitive epilepsies (a minority of patients).

Epilepsy is a clinical diagnosis. Investigations clarify aetiology and guide therapy but rarely prove the diagnosis on their own—a normal interictal EEG never excludes epilepsy.

Clinical assessment

• Eyewitness history: pre-event circumstances, aura, posture and colour change, duration, lateralising motor signs, postictal recovery profile—video on a phone is invaluable.
• Differentiate provoked from unprovoked: hypoglycaemia, electrolyte disturbance, alcohol withdrawal, eclampsia, drug toxicity, head trauma in the preceding week.
• Past medical history: febrile seizures, perinatal events, head injury, CNS infection, stroke, autoimmune disease, family history of epilepsy.
• Medication and substance review: enzyme-inducing or seizure-threshold-lowering drugs (bupropion, tramadol, fluoroquinolones), hormonal therapy, recreational substances.
• Targeted examination: focal deficits, neurocutaneous markers (tuberous sclerosis, neurofibromatosis), cognitive screen, and a careful cardiovascular examination to exclude syncope.

Laboratory investigations

• Electrolytes (sodium, calcium, magnesium), comprehensive metabolic panel, glucose, urea, creatinine.
• Complete blood count and liver function tests—baseline before antiseizure initiation and during episodes of unexplained illness on therapy.
• Urine drug screen and toxicology when relevant.
• Pregnancy test in any person of childbearing potential—mandatory before imaging, certain antiseizure choices, and most surgical decisions.
• Lumbar puncture when CNS infection or autoimmune encephalitis is suspected (after imaging).

EEG & imaging

• Routine EEG with sleep deprivation and hyperventilation activation increases yield; a single normal study does not rule out epilepsy.
• Prolonged or video EEG when events are frequent enough to capture, when classification is unclear, or to evaluate non-epileptic events.
• Brain MRI with an epilepsy-specific protocol is the imaging investigation of choice for new epilepsy diagnoses, except in self-limited childhood syndromes where it can be deferred or omitted per local guidance.
• CT is preferred acutely when there is focal deficit, head injury, anticoagulation, or rapid deterioration, with MRI as the elective follow-up.

Diagnostic thresholds at a glance

↔On a small screen, swipe or scroll sideways to see the full table.

A pragmatic mental model for nurses, junior doctors, and allied clinicians—medication selection and pathway activation remain prescriber- and protocol-led.

• New convulsive event: ABC, glucose, IV access; if seizing >5 min, give benzodiazepine and start the status pathway; otherwise observe and investigate.
• Seizure stops, patient recovers: 12-lead ECG, electrolytes, glucose, pregnancy test if applicable, neurology referral, and EEG/MRI as outpatient or inpatient depending on red flags.
• Known epilepsy with breakthrough seizures: review adherence, sleep, infection, alcohol, new prescriptions, and timing of last menstrual period; reconcile with pharmacy via medication reconciliation.
• Two appropriate drugs failed: escalate to a comprehensive epilepsy centre for surgical, neuromodulation, or dietary work-up rather than indefinite drug rotation.
• Pregnancy planning or new pregnancy: joint review with obstetrics and epilepsy specialists; never abruptly discontinue therapy without prescriber input.

Many transient events of altered awareness or movement mimic seizures. Misdiagnosis is common and costly—labelling syncope or psychogenic events as epilepsy exposes patients to unnecessary medication and driving restrictions, while missing genuine seizures delays neurology input.

↔On a small screen, swipe or scroll sideways to see the full table.

The ILAE conceptualises status epilepticus along two time points: t1, when the seizure is unlikely to terminate spontaneously (≈5 min for convulsive seizures), and t2, when long-term consequences become likely (≈30 min). Treatment must start at t1—waiting confers no benefit and worsens outcomes.

Stabilisation (0–5 minutes)

• Time the seizure; protect airway with lateral positioning and airway suctioning as needed; consider an oropharyngeal airway only if tolerated.
• High-flow oxygen, continuous SpO₂, cardiac monitoring, IV access, point-of-care glucose, and bloods including electrolytes, calcium, magnesium, troponin if indicated, and antiseizure drug levels.
• Treat hypoglycaemia (and give thiamine before glucose in alcohol-related presentations per local protocol).

First-line benzodiazepines (5–20 minutes)

• IV lorazepam 0.1 mg/kg (typically 4 mg in adults), repeat once after 5–10 min if seizure persists.
• IM midazolam 10 mg (≥40 kg) when no IV access—at least as effective as IV lorazepam in pre-hospital settings.
• Rectal or buccal diazepam for paediatrics or community settings per local pathway.
• Inadequate dosing is the single most common error—give the full first dose and the second dose on schedule rather than “a little” twice.

Second-line therapy (20–40 minutes)

• IV levetiracetam (60 mg/kg, max 4500 mg), IV fosphenytoin/phenytoin (20 mg phenytoin equivalents/kg), or IV valproate (40 mg/kg, avoid in suspected mitochondrial disease and pregnancy)—agents are equivalent in major trials, so local availability and patient comorbidity guide choice.
• Reassess airway, blood pressure, and ECG after each second-line load.

Refractory and super-refractory status (≥40 minutes)

• Anaesthetic infusions (midazolam, propofol, ketamine, or thiopental) with intubation, continuous EEG, and ICU-level support.
• Identify and treat the underlying cause (autoimmune, infection, metabolic, structural).
• Maintenance therapy is layered on once seizures are controlled; never extubate before EEG confirms cessation in non-convulsive forms.

Local algorithms (NICE NG217, AES 2016 guidance) differ in dose and timing; always default to the protocol active in your institution.

The aim is sustained seizure freedom with the fewest tolerated side effects, anchored by a confirmed seizure type and syndrome. Around 60–70% of patients achieve control on monotherapy; the remainder require optimisation, combination therapy, or non-drug interventions.

First-line antiseizure medications by seizure type

↔On a small screen, swipe or scroll sideways to see the full table.

Adjuncts & broader-spectrum agents

• Lacosamide, perampanel, brivaracetam, eslicarbazepine, zonisamide for refractory focal epilepsy.
• Clonazepam and phenobarbital remain useful in specific populations and resource-limited settings.
• Gabapentin and pregabalin are reserved for focal epilepsy or comorbid neuropathic pain—less effective overall and not for generalised epilepsies.
• Primidone is rarely first-line because of sedation and interaction burden.

Drug-resistant epilepsy & non-pharmacological options

• Resective surgery for well-localised lesions (especially mesial temporal sclerosis) can be curative—earlier referral correlates with better outcomes.
• Vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation reduce seizure burden when surgery is not feasible.
• Ketogenic and modified Atkins diets are evidence-based options, especially in paediatrics and selected adults.
• Cannabidiol (Epidyolex/Epidiolex) is licensed for Lennox–Gastaut, Dravet, and tuberous sclerosis–related seizures under specialist supervision.

Therapeutic drug monitoring & safety surveillance

• Phenytoin, carbamazepine, valproate, and phenobarbital have established target ranges—use levels for adherence checks, breakthrough seizures, suspected toxicity, pregnancy, and renal/hepatic disease.
• Newer agents (levetiracetam, lacosamide, brivaracetam, perampanel) are dosed clinically with levels reserved for specific scenarios.
• Counsel on rash surveillance for first 3 months on lamotrigine, carbamazepine, oxcarbazepine, and phenytoin—any mucosal involvement or systemic upset triggers immediate review.

Women of childbearing potential, pregnancy, and lactation

• Counsel on contraception interactions: enzyme-inducing drugs (carbamazepine, phenytoin, phenobarbital, primidone, topiramate ≥200 mg) reduce hormonal contraceptive efficacy; consider intrauterine devices or specialist advice.
• Sodium valproate is teratogenic and impairs neurodevelopment—use in women of childbearing potential is restricted to risk-acknowledgement programmes (e.g. MHRA Pregnancy Prevention Programme in the UK).
• Lamotrigine and levetiracetam have the most reassuring pregnancy data among commonly used agents; lamotrigine clearance increases markedly through pregnancy and dose adjustments are routinely needed.
• Folic acid supplementation per local guidance, planned pregnancies through epilepsy services, and shared antenatal care reduce maternal and fetal risk; never abruptly discontinue therapy on discovery of pregnancy.

Older adults

• Stroke is the leading cause of new-onset epilepsy after 60—investigate vascular risk and consider stroke prevention alongside seizure control.
• Polypharmacy interactions, falls, and cognitive load favour low-dose lamotrigine or levetiracetam over enzyme inducers.
• Consider formal fall risk assessment and bone health review.

Children and adolescents

• Diagnosis is heavily syndrome-driven; many self-limited childhood epilepsies have excellent prognosis with monotherapy or, for some, no treatment at all.
• School liaison, learning support, and transition-of-care planning to adult services are core nursing tasks.
• Avoid sodium-channel agents in syndromes with prominent absence/myoclonic features unless prescriber-led.

Renal and hepatic impairment

• Levetiracetam, lacosamide, gabapentin, pregabalin, and topiramate require dose adjustment in renal impairment.
• Valproate, carbamazepine, lamotrigine, and phenytoin need caution and surveillance in significant hepatic disease.

• Status epilepticus with hypoxic-ischaemic injury, rhabdomyolysis, aspiration pneumonia, and cardiac dysrhythmia.
• Sudden unexpected death in epilepsy (SUDEP)—incidence ~1 per 1000 patient-years overall, higher with frequent generalised tonic-clonic seizures, nocturnal events, and poor adherence.
• Injury: tongue laceration, fractures, burns, drowning, road traffic incidents; targeted by safety counselling and statutory driving restrictions.
• Cognitive and psychiatric comorbidity: depression, anxiety, postictal psychosis, and chronic memory complaints—screen at every annual review.
• Adverse drug reactions: sedation, ataxia, hyponatraemia (carbamazepine, oxcarbazepine), weight change, behavioural disturbance (levetiracetam), kidney stones or paraesthesia (topiramate), and severe rash (lamotrigine, carbamazepine, oxcarbazepine, phenytoin).
• Reproductive outcomes: teratogenicity of valproate, neural tube defects, neurodevelopmental delay—mitigated by rational drug choice and folate.
• Bone health: long-term enzyme-inducing therapy is associated with reduced bone mineral density; review supplementation and DEXA per local pathway.

Can epilepsy be prevented?

Practical clinician-facing measures

• Treat vascular risk factors aggressively to limit post-stroke epilepsy.
• Helmet use, road safety, and falls prevention to reduce traumatic brain injury–related epilepsy.
• Vaccination, sanitation, and parasite control to reduce CNS infections in endemic settings.
• Sleep hygiene, alcohol moderation, and adherence support to limit breakthrough seizures in established disease.
• Medication reconciliation at every transition of care—new antibiotics, antidepressants, and analgesics commonly destabilise control.
• Pre-conception counselling for women on potentially teratogenic regimens, with timely switching where appropriate.

Outcomes vary widely with seizure type, syndrome, aetiology, and treatment response. Around 60–70% of patients achieve seizure freedom on the first or second appropriately chosen drug; the remainder fall into the drug-resistant group, where structured surgical and neuromodulation work-up improves outcomes far more reliably than continued drug rotation.

• Self-limited childhood syndromes (e.g. self-limited epilepsy with centrotemporal spikes) frequently remit by adolescence.
• Juvenile myoclonic epilepsy responds well to broad-spectrum drugs but typically requires lifelong therapy.
• Drug-resistant temporal lobe epilepsy with hippocampal sclerosis can achieve seizure freedom in 60–70% of carefully selected surgical candidates.
• Mortality remains higher than the general population, driven by status epilepticus, SUDEP, accidents, and underlying aetiology—all addressable through specialist follow-up.

Real-world habits that prevent harm and accelerate the right specialist input:

• Document seizures with timed, behavioural language—“tonic stiffening 30 s, clonic jerks 90 s, postictal somnolence 25 min”—not generic “patient seized”.
• Always check capillary glucose and last antiseizure dose before assuming the event is breakthrough epilepsy.
• Reconcile every new prescription—antibiotics (especially fluoroquinolones, carbapenems), antidepressants, tramadol, hormonal contraception, and over-the-counter products.
• Reinforce that driving must stop after any new seizure and document the conversation; do not assume someone else has had it.
• Use structured medication administration and high-alert checks for IV antiseizure drugs—infusion errors are a recurring incident theme.
• Address psychiatric comorbidity proactively—many SSRIs are safe and improve adherence; bupropion remains the notable seizure-threshold-lowering exception.

Use during admission, breakthrough seizures, or new therapy initiation; tailor to local protocols.

• Vital signs & airway: continuous SpO₂, ECG, BP every 15 min in active or recent status; aspiration precautions; suction at bedside.
• Neuro observations: structured neurological assessment, GCS/AVPU, pupillary assessment, lateralising signs, and trending postictal recovery.
• Seizure log: timed onset, semiology, duration, lateralisation, recovery time, and rescue medication given—shared at handoff.
• Safety: bed rails padded, suction and oxygen ready, height restrictions, supervised bathing/showering, formal fall risk assessment, and lateral recovery positioning after events.
• Drug surveillance: rash check (especially first 3 months), mood and behaviour change, sodium for carbamazepine/oxcarbazepine, LFTs for valproate/lamotrigine, ammonia if encephalopathy on valproate.
• Education touchpoints: medication times, missed-dose plan, driving rules, swimming and bathing safety, pregnancy planning, SUDEP discussion documented at least annually.

Patients, carers, and ward teams should treat the following as 999/911/2222 events depending on setting—do not wait for routine review.

• Any convulsive seizure lasting ≥5 minutes, or a second seizure before full recovery from the first.
• First-ever seizure, or seizure with focal weakness, severe headache, fever, neck stiffness, head injury, or in pregnancy.
• Seizure in water, with serious injury, or with prolonged cyanosis or apnoea.
• Failure to return to baseline awareness within ~30 minutes—suspect non-convulsive status epilepticus.
• New rash with mucosal involvement or systemic symptoms within weeks of starting lamotrigine, carbamazepine, oxcarbazepine, or phenytoin.
• Suicidal ideation emerging on antiseizure therapy—class warning that warrants immediate clinical assessment.

Until help arrives: protect from injury, time the event, place the patient in the recovery position once movements ease, give organisation-approved rescue medication only if competent, and capture eyewitness video where possible.

Nursing priorities span acute seizure control, longitudinal monitoring, and the social, occupational, and reproductive consequences of living with epilepsy.

Acute seizure response

• Stay with the patient, time the seizure, protect the head, remove hazards, and avoid restraining limbs or placing objects in the mouth.
• Once movements ease, place laterally and apply oxygen via mask; suction visible secretions only.
• Prepare benzodiazepine rescue per local protocol; ensure IV access, glucose, and crash trolley are accessible.
• Document semiology in real time—timed onset, motor pattern, lateralisation, autonomic features, recovery profile.

Admission & ongoing inpatient care

• Use structured admission assessment to capture seizure history, triggers, current regimen, allergies, and recent changes.
• Pad bed rails, position suction and oxygen at the bedside, and document seizure precautions on the bed-board.
• Reconcile antiseizure medications on admission, before transfers, and at discharge—missed doses are a leading cause of inpatient breakthrough seizures.
• Use telemetry monitoring when indicated for cardiac causes of collapse or for severe drug toxicity.

Therapy initiation & titration

• Counsel on dose-by-dose rash, mood, and behavioural changes—particularly during the first 3 months.
• Schedule baseline and surveillance bloods (LFTs, FBC, sodium, drug levels) per pathway.
• Confirm understanding of missed-dose plans and out-of-hours escalation routes—nurse-led helplines work best when the patient knows the number and the threshold.

Psychosocial & legal counselling

• Discuss driving restrictions clearly and document the conversation; provide written information and the licensing authority’s notification process.
• Address employment, alcohol, sleep, and water safety; signpost epilepsy charities and peer support.
• Screen for depression and anxiety at every contact—untreated comorbidity worsens adherence and quality of life.

Red flags for deterioration

• Any seizure ≥5 min, recurrent seizures without recovery, or persistent altered mental status.
• New focal deficit, fever, severe headache, or signs of raised intracranial pressure.
• Mucocutaneous rash, eosinophilia, or systemic illness on a recently started antiseizure drug.
• Worsening seizure frequency despite reported adherence—prompt regimen review rather than waiting for the next clinic.
• Pregnancy disclosure on a teratogenic regimen—same-day epilepsy and obstetric review.

Education, discharge, and evaluation

• Use teach-back on seizure first-aid, recovery position, and when to call emergency services.
• Confirm written seizure action plan, follow-up appointment, prescription supply, and licensing authority paperwork before discharge.
• Evaluate effectiveness through trended seizure diaries, adherence metrics, mood scores, and quality-of-life feedback—not single snapshots.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of epilepsy recognition (focal vs generalised, EEG / MRI work-up timing), structured antiseizure-medication titration / monitoring and the convulsive-status-epilepticus / SUDEP / driving / pregnancy red flags.